In patients on suppressive ART regimens, consideration should be given to differences in side effect profile, drug–drug interaction (DDIs) and drug resistance patterns before switching any ARV component.

In patients with previous NRTI resistance mutations, we recommend against switching a PI/r to either an NNRTI or an INI as the third agent.